Fundación Instituto Leloir, IIBBA, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina.
PLoS One. 2012;7(9):e45705. doi: 10.1371/journal.pone.0045705. Epub 2012 Sep 24.
Lumazine synthase from Brucella spp. (BLS) is a highly immunogenic decameric protein. It is possible to insert foreign peptides or proteins at its ten-amino acid termini. These chimeras elicit systemic and oral immunity without adjuvants, which are commonly needed in the formulation of subunit-based vaccines. Here, we show that BLS induces the cross presentation of a covalently attached peptide OVA(257-264) and a specific cytotoxic response to this peptide in the absence of adjuvants. Unlike other subunit-based vaccines, this chimera induces rapid activation of CTLs and a specific cytotoxic response, making this polymeric protein an ideal antigen carrier for vaccine development. Adoptive transfer of transgenic OT-I T cells revealed efficient cross presentation of BLS-OVA(257-264)in vivo. BLS-OVA(257-264) immunization induced the proliferation of OVA(257-264)-specific CD8+ lymphocytes and also increased the percentage of OVA(257-264)-specific CD8+ cells expressing the early activation marker CD69; after 5 days, the percentage of OVA(257-264)-specific CD8+ cells expressing high levels of CD44 increased. This cell subpopulation showed decreased expression of IL-7Rα, indicating that BLS-OVA(257-264) induced the generation of CD8+ effector cells. BLS-OVA(257-264) was cross presented in vitro independently of the presence of a functional TLR4 in the DCs. Finally, we show that immunization of wild type mice with the chimera BLS-OVA(257-264) without adjuvants induced a strong OVA(257-264)-specific effector cytotoxic response. This cytotoxicity is dependent on TLR4 as is not induced in mice lacking a functional receptor. These data show that TLR4 signaling is necessary for the induction of a cytotoxic response but not for antigen cross presentation.
布鲁氏菌属的光氨酸合酶(BLS)是一种高度免疫原性的十聚体蛋白。可以在其十个氨基酸末端插入外源肽或蛋白。这些嵌合体在没有佐剂的情况下诱导全身和口服免疫,而佐剂通常是亚单位疫苗配方所必需的。在这里,我们表明 BLS 诱导共价连接的肽 OVA(257-264)的交叉呈递,并且在没有佐剂的情况下对该肽产生特异性细胞毒性反应。与其他亚单位疫苗不同,这种嵌合体诱导 CTL 的快速激活和特异性细胞毒性反应,使这种聚合蛋白成为疫苗开发的理想抗原载体。转基因 OT-I T 细胞的过继转移显示 BLS-OVA(257-264)在体内的有效交叉呈递。BLS-OVA(257-264)免疫诱导 OVA(257-264)特异性 CD8+淋巴细胞的增殖,并且还增加了表达早期激活标记物 CD69的 OVA(257-264)特异性 CD8+细胞的百分比;5 天后,表达高水平 CD44 的 OVA(257-264)特异性 CD8+细胞的百分比增加。该细胞亚群表达的 IL-7Rα减少,表明 BLS-OVA(257-264)诱导了 CD8+效应细胞的产生。BLS-OVA(257-264)在体外的交叉呈递独立于 DC 中功能性 TLR4 的存在。最后,我们表明,在没有佐剂的情况下,用嵌合体 BLS-OVA(257-264)免疫野生型小鼠诱导了强烈的 OVA(257-264)特异性效应细胞细胞毒性反应。这种细胞毒性依赖于 TLR4,因为在缺乏功能性受体的小鼠中不会诱导。这些数据表明 TLR4 信号传导对于诱导细胞毒性反应是必要的,但不是抗原交叉呈递所必需的。